Food and Behaviour Research

Donate Log In

Fructose stimulated de novo lipogenesis is promoted by inflammation

Todoric J, Caro G, Reibe S, Henstridge D, Green C, Vrbanac A, Ceteci F, Conche C, McNulty R, Shalapour S, Taniguchi K, Meikle P, Watrous J, Moranchel R, Najhawan M, Jain M, Liu X, Kisseleva T, Diaz-Meco M, Moscat J, Knight R, Greten F, Lau L, Metallo C, Febbraio M, Karin M (2020) Nature Metabolism 2020 Aug 24 doi: 10.1038/s42255-020-0261-2 

Web URL: Read this and related articles on PubMed

Abstract:

Benign hepatosteatosis, affected by lipid uptake, de novo lipogenesis and fatty acid (FA) oxidation, progresses to non-alcoholic steatohepatitis (NASH) on stress and inflammation. A key macronutrient proposed to increase hepatosteatosis and NASH risk is fructose. Excessive intake of fructose causes intestinal-barrier deterioration and endotoxaemia. However, how fructose triggers these alterations and their roles in hepatosteatosis and NASH pathogenesis remain unknown. Here we show, using mice, that microbiota-derived Toll-like receptor (TLR) agonists promote hepatosteatosis without affecting fructose-1-phosphate (F1P) and cytosolic acetyl-CoA. Activation of mucosal-regenerative gp130 signalling, administration of the YAP-induced matricellular protein CCN1 or expression of the antimicrobial peptide Reg3b (beta) peptide counteract fructose-induced barrier deterioration, which depends on endoplasmic-reticulum stress and subsequent endotoxaemia. Endotoxin engages TLR4 to trigger TNF production by liver macrophages, thereby inducing lipogenic enzymes that convert F1P and acetyl-CoA to FA in both mouse and human hepatocytes.